MedTrace Logo

Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy

NCT02609828 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 156

Last updated 2023-02-16

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether tanezumab is effective in the treatment of cancer pain due to bone metastasis in patients already taking background opioid therapy.

Conditions

  • Bone Metastasis
  • Cancer Pain

Interventions

DRUG

Tanezumab

Subcutaneous study treatment (tanezumab 20 mg or matched placebo) dosed at 8 week intervals.

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-28
Primary Completion
2020-09-17
Completion
2021-06-25
FDA Drug
Yes

Countries

  • Argentina
  • Australia
  • Austria
  • Brazil
  • Chile
  • China
  • Czechia
  • Hungary
  • Israel
  • Japan
  • Poland
  • Romania
  • Slovakia
  • South Korea
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02609828 on ClinicalTrials.gov